TY - JOUR
T1 - Ultrasound-mediated drug delivery to the brain
T2 - principles, progress and prospects
AU - Dasgupta, Anshuman
AU - Liu, Mengjiao
AU - Ojha, Tarun
AU - Storm, Gert
AU - Kiessling, Fabian
AU - Lammers, Twan
N1 - Publisher Copyright:
© 2016 Elsevier Ltd
PY - 2016/6/1
Y1 - 2016/6/1
N2 - The blood–brain barrier (BBB) limits drug delivery to the central nervous system. When combined with microbubbles, ultrasound can transiently permeate blood vessels in the brain. This approach, which can be referred to as sonoporation or sonopermeabilization, holds significant promise for shuttling large therapeutic molecules, such as antibodies, growth factors and nanomedicine formulations, across the BBB. We here describe the basic principles of BBB permeation using ultrasound and microbubbles, and we summarize several (pre-) clinical studies showing the potential of BBB opening for improving the treatment of cancer and neurodegenerative disorders.
AB - The blood–brain barrier (BBB) limits drug delivery to the central nervous system. When combined with microbubbles, ultrasound can transiently permeate blood vessels in the brain. This approach, which can be referred to as sonoporation or sonopermeabilization, holds significant promise for shuttling large therapeutic molecules, such as antibodies, growth factors and nanomedicine formulations, across the BBB. We here describe the basic principles of BBB permeation using ultrasound and microbubbles, and we summarize several (pre-) clinical studies showing the potential of BBB opening for improving the treatment of cancer and neurodegenerative disorders.
KW - 2023 OA procedure
UR - http://www.scopus.com/inward/record.url?scp=85002913087&partnerID=8YFLogxK
U2 - 10.1016/j.ddtec.2016.07.007
DO - 10.1016/j.ddtec.2016.07.007
M3 - Review article
C2 - 27986222
SN - 1740-6749
VL - 20
SP - 41
EP - 48
JO - Drug Discovery Today: Technologies
JF - Drug Discovery Today: Technologies
ER -
